AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15885986 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-sulbactam (PIP‐SBT)
Number of subjects: 215
Study 15885986 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam (PIP‐TAZ)
Number of subjects: 215
Study 11819108 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-sutured anastomoses
Number of subjects: 30
Study 11819108 — intervention group
Group type: COMPARATOR
Intervention: Biofragmentable anastomotic ring (BAR)
Number of subjects: 30
Study 11819108 — intervention group
Group type: COMPARATOR
Intervention: Stapled anastomoses
Number of subjects: 30
Study 9857541 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound technique for prosthetic treatment planning and observation
Number of subjects: 180
Study 9857541 — intervention group
Group type: COMPARATOR
Intervention: Standard prosthetic treatment planning based on subjective estimation
Number of subjects: 180
Study 8573425 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiludronate 200 mg
Number of subjects: 139
Study 8573425 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiludronate 400 mg
Number of subjects: 139
Study 8573425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 2569665 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam (Odipam)
Number of subjects: 0
Study 2569665 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study 7028088 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate eye drops
Number of subjects: 39
Study 7028088 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone phosphate eye drops
Number of subjects: 39
Study 7028088 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 39
Study 30431383 — intervention group
Group type: EXPERIMENTAL
Intervention: HAVi administered alone
Number of subjects: 4374
Study 30431383 — intervention group
Group type: EXPERIMENTAL
Intervention: HAVi administered concomitantly with other pediatric vaccines
Number of subjects: 4374
Study 28087723 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic propranolol (0.5 mg/kg/dose every 12 hours)
Number of subjects: 109
Study 28087723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 27518319 — intervention group
Group type: EXPERIMENTAL
Intervention: Itopride 100 mg t.d.s.
Number of subjects: 60
Study 27518319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 24813196 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa on cycle day 4 (CD4)
Number of subjects: 59
Study 24813196 — intervention group
Group type: COMPARATOR
Intervention: Corifollitropin alfa on cycle day 2 (CD2)
Number of subjects: 59
Study 22366526 — intervention group
Group type: EXPERIMENTAL
Intervention: FT multimodal rehabilitation programme
Number of subjects: 99
Study 22366526 — intervention group
Group type: COMPARATOR
Intervention: Traditional perioperative care (non‐FT group)
Number of subjects: 99
Study 20384754 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-depth fractional CO(2) resurfacing
Number of subjects: 15
Study 18534230 — intervention group
Group type: EXPERIMENTAL
Intervention: New amino acid-based formula (AAF)
Number of subjects: 197
Study 18534230 — intervention group
Group type: COMPARATOR
Intervention: Control extensively hydrolyzed formula (EHF)
Number of subjects: 197
Study 16003455 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐monitored, home‐based rehabilitation
Number of subjects: 240
Study 16003455 — intervention group
Group type: COMPARATOR
Intervention: Hospital‐based, outpatient rehabilitation
Number of subjects: 240
Study 12430877 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Therapy II (TT II) with thalidomide at a starting dose of 400 mg
Number of subjects: 231
Study 12430877 — intervention group
Group type: COMPARATOR
Intervention: Total Therapy II (TT II) without thalidomide (data still blinded)
Number of subjects: 231
Study 10071916 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate treatment
Number of subjects: 67
Study 7480526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 16
Study 2147887 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinylestradiol and 150 micrograms desogestrel (EE/DG)
Number of subjects: 0
Study 2147887 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinylestradiol and 75 micrograms gestodene (EE/GSD)
Number of subjects: 0
Study 2147887 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EE/DG and EE/GSD
Number of subjects: 0
Study 7039666 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral timolol (5 mg to 30 mg per day)
Number of subjects: 12
Study 7039666 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of timolol and adrenaline
Number of subjects: 12
Study 30892293 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball-retained overdentures
Number of subjects: 24
Study 30892293 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar-retained overdentures
Number of subjects: 24
Study 30892293 — intervention group
Group type: EXPERIMENTAL
Intervention: Locator-retained overdentures
Number of subjects: 24
Study 30892293 — intervention group
Group type: COMPARATOR
Intervention: Conventional dentures
Number of subjects: 24
Study 30892293 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing of hard food
Number of subjects: 24
Study 30892293 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing of soft food
Number of subjects: 24
Study 28619034 — intervention group
Group type: EXPERIMENTAL
Intervention: New community-based intervention model (NC model)
Number of subjects: 901
Study 28619034 — intervention group
Group type: COMPARATOR
Intervention: Traditional community intervention model (TC model)
Number of subjects: 901
Study 26408273 — intervention group
Group type: EXPERIMENTAL
Intervention: sulodexide 500 lipasemic units twice daily
Number of subjects: 615
Study 26408273 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 615
Study 26408273 — intervention group
Group type: EXPERIMENTAL
Intervention: sulodexide
Number of subjects: 615
Study 26408273 — intervention group
Group type: COMPARATOR
Intervention: sulodexide and placebo
Number of subjects: 615
Study 23603824 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg)
Number of subjects: 243
Study 23603824 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (20 mg)
Number of subjects: 243
Study 20924753 — intervention group
Group type: EXPERIMENTAL
Intervention: TFMPP (0.94 mg/kg, oral)
Number of subjects: 30
Study 20924753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19763062 — intervention group
Group type: EXPERIMENTAL
Intervention: Rub-and-spray method (group G, n=10)
Number of subjects: 20
Study 19763062 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C, n=10)
Number of subjects: 20
Study 16673051 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 24
Study 15090395 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (porcine graft fixed in porcine tibia)
Number of subjects: 3
Study 15090395 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (human hamstring graft and porcine tibia)
Number of subjects: 3
Study 15090395 — intervention group
Group type: COMPARATOR
Intervention: Group 3 (human graft and tibia)
Number of subjects: 3
Study 11572892 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma von Willebrand factor levels above the median
Number of subjects: 160
Study 9786313 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan 300 to 350 mg/m2 every 3 weeks
Number of subjects: 0
Study 9786313 — intervention group
Group type: COMPARATOR
Intervention: infusional 5-FU with or without leucovorin
Number of subjects: 0
Study 8156337 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin
Number of subjects: 206
Study 8156337 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 206
Study 8156337 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (in elderly patients)
Number of subjects: 206
Study 8156337 — intervention group
Group type: COMPARATOR
Intervention: Control (in elderly patients)
Number of subjects: 206
Study 3047691 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group with nursing intervention program including discussion of assessment data, identification of problems, and establishment of goals
Number of subjects: 103
Study 3047691 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study 3047691 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 103
Study 28459350 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented feedback (aF) about ground-contact time (GCT) during 8 high-intensity interval sessions over 4 weeks
Number of subjects: 30
Study 28459350 — intervention group
Group type: COMPARATOR
Intervention: Control group 1 (CG1) - trained with the intervention group but received no feedback
Number of subjects: 30
Study 28459350 — intervention group
Group type: COMPARATOR
Intervention: Control group 2 (CG2) - followed their own training routine
Number of subjects: 30
Study 28060148 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg ziv-aflibercept (0.08 mL) intravitreal injection
Number of subjects: 20
Study 26335105 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion axillary treatment (completion axillary lymph node dissection or axillary radiation therapy)
Number of subjects: 878
Study 26335105 — intervention group
Group type: COMPARATOR
Intervention: No completion axillary treatment
Number of subjects: 878
Study 22857386 — intervention group
Group type: EXPERIMENTAL
Intervention: basic numeric FOP label
Number of subjects: 430
Study 22857386 — intervention group
Group type: EXPERIMENTAL
Intervention: numeric FOP label with 'high' and 'low' sodium content descriptors
Number of subjects: 430
Study 22857386 — intervention group
Group type: EXPERIMENTAL
Intervention: detailed Traffic Light (TL) label with colour coding, content descriptors and numeric information
Number of subjects: 430
Study 22857386 — intervention group
Group type: EXPERIMENTAL
Intervention: simple TL label with no numeric information
Number of subjects: 430
Study 22857386 — intervention group
Group type: COMPARATOR
Intervention: control condition with no FOP label
Number of subjects: 430
Study 21156974 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg (2 capsules) in recovery room, followed by celecoxib 200 mg (1 capsule) twice a day + placebo at bedtime for 3 days after surgery.
Number of subjects: 180
Study 21156974 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg (1 tablet) in recovery room, followed by 400 mg orally 3 times a day for 3 days after surgery.
Number of subjects: 180
Study 21156974 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (2 placebo capsules or 1 placebo tablet in recovery room, followed by placebo for 3 days after surgery).
Number of subjects: 180
Study 19006062 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal packing after septoplasty
Number of subjects: 88
Study 19006062 — intervention group
Group type: COMPARATOR
Intervention: No nasal packing after septoplasty
Number of subjects: 88
Study 15814212 — intervention group
Group type: EXPERIMENTAL
Intervention: Clustered Care following blood collection (PCC)
Number of subjects: 54
Study 15814212 — intervention group
Group type: COMPARATOR
Intervention: Routine care-giving tasks (RCC)
Number of subjects: 54
Study 12459686 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (CSE) analgesia
Number of subjects: 1054
Study 12459686 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose infusion (LDI)
Number of subjects: 1054
Study 12459686 — intervention group
Group type: COMPARATOR
Intervention: Traditional epidural analgesia
Number of subjects: 1054
Study 10488711 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatocellular carcinoma patients with non-cirrhotic livers
Number of subjects: 30
Study 10488711 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intake > or =30 g/d
Number of subjects: 30
Study 10488711 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 30
Study 10488711 — intervention group
Group type: EXPERIMENTAL
Intervention: Serological markers of HBV or HCV
Number of subjects: 30
Study 10488711 — intervention group
Group type: EXPERIMENTAL
Intervention: No exposure to alcohol or tobacco and no serological markers of HBV or HCV
Number of subjects: 30
Study 10488711 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological changes in the non-tumorous liver
Number of subjects: 30
Study 8729094 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in n-6 linoleic acid or n-3 alpha-linolenic acid with or without fish oil supplements (n-3 derivatives)
Number of subjects: 519
Study 8729094 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in PUFA (either n-3 or n-6 or fish oils)
Number of subjects: 519
Study 8729094 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dietary intake of PUFA
Number of subjects: 519
Study 8729094 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced dietary intake of PUFA
Number of subjects: 519
Study 1908190 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and transcutaneous stimulation analgesia supplemented by small doses of fentanyl (mean 1.2 micrograms/kg, SD 1.7)
Number of subjects: 29
Study 1908190 — intervention group
Group type: COMPARATOR
Intervention: Moderate-dose fentanyl anaesthesia (mean 22.9 micrograms/kg, SD 2.8)
Number of subjects: 29
Study 6580492 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine (N‐acetyl‐L‐cysteine) 1 hour before doxorubicin administration
Number of subjects: 20
Study 6580492 — intervention group
Group type: COMPARATOR
Intervention: Placebo 1 hour before doxorubicin administration
Number of subjects: 20
Study 30938315 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin plus ciclosporin
Number of subjects: 0
Study 30938315 — intervention group
Group type: COMPARATOR
Intervention: Intravenous immunoglobulin
Number of subjects: 0
Study 29967037 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management (daily home BP monitoring and automated medication reduction via telemonitoring)
Number of subjects: 91
Study 29967037 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management
Number of subjects: 91
Study 29967037 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 91
Study 27301277 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine followed by rituximab
Number of subjects: 80
Study 25364873 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin injections
Number of subjects: 50
Study 25364873 — intervention group
Group type: COMPARATOR
Intervention: Oral antidiabetic drugs (OADs)
Number of subjects: 50
Study 22409418 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1%
Number of subjects: 0
Study 22409418 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (0.03% and 0.1%)
Number of subjects: 0
Study 22409418 — intervention group
Group type: COMPARATOR
Intervention: Pimecrolimus 1%
Number of subjects: 0
Study 21140698 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ilioinguinal nerve excision (INE)
Number of subjects: 97
Study 16228107 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC) 2 mg/kg daily for 12 months, then 1 mg/kg daily
Number of subjects: 60
Study 16228107 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZ) 2.5 mg/kg daily for 12 months, then 2 mg/kg daily
Number of subjects: 60
Study 14602794 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol-17 beta (E(2))
Number of subjects: 6
Study 10757579 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1% with clonidine 2 microg/kg (1 ml/kg)
Number of subjects: 40
Study 10757579 — intervention group
Group type: COMPARATOR
Intervention: Plain ropivacaine 0.2% (1 ml/kg)
Number of subjects: 40
Study 8836275 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized tetracaine 0.5 mg/kg
Number of subjects: 30
Study 8836275 — intervention group
Group type: COMPARATOR
Intervention: Nebulized saline
Number of subjects: 30
Study 1576071 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid (1 g three times daily)
Number of subjects: 28
Study 1576071 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg three times daily)
Number of subjects: 28
Study 1576071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 3930128 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 unit/h aVP infusion
Number of subjects: 4
Study 3930128 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 unit/h aVP infusion
Number of subjects: 4
Study 3930128 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 unit/h aVP infusion
Number of subjects: 4
Study 30939213 — intervention group
Group type: EXPERIMENTAL
Intervention: Na control (individually and automatically adjusted dialysate sodium concentration)
Number of subjects: 31
Study 30939213 — intervention group
Group type: COMPARATOR
Intervention: standard fixed Na (fixed dialysate sodium 138 mmol/L)
Number of subjects: 31
Study 29493395 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical azithromycin 15 mg/g ophthalmic solution, used twice a day for 3 days and then once a day until treatment completion (1 month).
Number of subjects: 30
Study 29493395 — intervention group
Group type: COMPARATOR
Intervention: Oral azithromycin 250 mg tablets, 1×2 tablets (500 mg) on the first day, then 1×1 tablet (250 mg) for 4 days, with 3 cycles of treatment and 5-day intervals.
Number of subjects: 30
Study 28639865 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumac juice
Number of subjects: 40
Study 28639865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 24671897 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily monitored device-based parameters (heart rate, thoracic impedance, HR variability, physical activity)
Number of subjects: 96
Study 24671897 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of HR and TI with LVEF and NT-proBNP
Number of subjects: 96
Study 22545373 — intervention group
Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 35
Study 22545373 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 35
Study 20182456 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/Hydrochlorothiazide combination (320/25 mg)
Number of subjects: 675
Study 20182456 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (320 mg)
Number of subjects: 675
Study 20182456 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25 mg)
Number of subjects: 675
Study 20182456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 675
Study 18625166 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician recommendation for CRC screening
Number of subjects: 15
Study 18625166 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational materials (videotapes, written materials)
Number of subjects: 15
Study 18625166 — intervention group
Group type: EXPERIMENTAL
Intervention: Frank and informative dialogue about patient's concerns
Number of subjects: 15
Study 15704683 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate supplement in Group I (n = 25)
Number of subjects: 64
Study 15704683 — intervention group
Group type: COMPARATOR
Intervention: No intervention in Group II (n = 39)
Number of subjects: 64
Study 11809596 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide/erythromycin combination (BP/E)
Number of subjects: 40
Study 11809596 — intervention group
Group type: COMPARATOR
Intervention: Benzoyl peroxide (BP)
Number of subjects: 40
Study 10366088 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 DEX DDS (60 microg dexamethasone)
Number of subjects: 90
Study 10366088 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 DEX DDS (60 microg dexamethasone)
Number of subjects: 90
Study 10366088 — intervention group
Group type: COMPARATOR
Intervention: Placebo DDS (no active drug)
Number of subjects: 90
Study 10366088 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 90
Study 10366088 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX DDS (1 or 2 doses)
Number of subjects: 90
Study 7746691 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (n = 21), administered twice daily for 2 days
Number of subjects: 40
Study 7746691 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 19), administered twice daily for 2 days
Number of subjects: 40
Study 1791611 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 32
Study 1791611 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 32
Study 7272145 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 105
Study 7272145 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 10 mg
Number of subjects: 105
Study 7272145 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 5 mg and Diazepam 5 mg (combination)
Number of subjects: 105
Study 31943693 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB; Cardionovum, Bonn, Germany)
Number of subjects: 230
Study 31943693 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stent (DES; Medtronic, Minneapolis, Minnesota)
Number of subjects: 230
Study 30875487 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-MTX
Number of subjects: 566
Study 30875487 — intervention group
Group type: COMPARATOR
Intervention: C-MTX
Number of subjects: 566
Study 28444178 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid procedure (coronary artery bypass grafting performed on the beating heart with cardiopulmonary bypass support followed by cardioplegic arrest for the valve procedure)
Number of subjects: 160
Study 28444178 — intervention group
Group type: COMPARATOR
Intervention: Conventional procedure (both procedures under cardioplegic arrest)
Number of subjects: 160
Study 28444178 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid procedure
Number of subjects: 160
Study 25311934 — intervention group
Group type: EXPERIMENTAL
Intervention: mannose 6‐phosphate
Number of subjects: 39
Study 25311934 — intervention group
Group type: COMPARATOR
Intervention: standard care
Number of subjects: 39
Study 23920048 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg of GnRH antagonist daily for 7 days
Number of subjects: 30
Study 23920048 — intervention group
Group type: COMPARATOR
Intervention: Standard flexible GnRH antagonist protocol
Number of subjects: 30